HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	10/19/2015 11:16:42 AM
	of 1022

GHENT, Belgium, 15 October 2015 - Ablynx [Euronext Brussels: ABLX] today announced that it has achieved pre-clinical proof-of-concept with a Nanobody construct as part of its immuno-oncology collaboration with Merck & Co., Inc. (“Merck”), triggering a €3.5 million milestone payment to Ablynx. This collaboration with Merck includes the discovery and development of up to 17 Nanobody programmes against individual protein targets and target combinations (mono-specific and multi-specific Nanobodies) for application in immuno-oncology indications. This Nanobody construct is a selective bi-specific molecule that potently binds to two different immune modulators, proteins believed to be targets for the development of important cancer immunotherapies. The results from the pre-clinical study in relevant tumour models demonstrated that this bi-specific Nanobody construct potently inhibits tumour growth.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next